Moderna, Inc. Common Stock
MRNAStock
$63.15+116.21%52W
Market Cap$25.08B
P/E—
Div yield—
Beta0.87
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)80.79%
Price vs S&P 500 (4W)22.65%
VGM Score57.14
Market Capitalization$25.08B
Earnings Surprise History
Q1 26-3.40est. -4.04
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.80
2.80
3.23
2.80
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $341.79 |
About
Moderna is a biotechnology company leveraging its validated mRNA platform to develop therapeutics across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company commercially validated its technology with its FDA-authorized COVID-19 vaccine in 2020. As of August 2025, Moderna maintains a pipeline of 35 mRNA candidates in clinical development.